Duh Mei Sheng, Hackshaw Michelle D, Ivanova Jasmina I, Kruse Gregory, Miller Lesley-Ann N, Lefebvre Patrick, Karner Paul, Wong Bruce
Analysis Group, Inc., 111 Huntington Avenue, Tenth Floor, Boston, MA 02199, USA.
GlaxoSmithKline, Philadelphia, PA 19102, USA.
Sarcoma. 2013;2013:947413. doi: 10.1155/2013/947413. Epub 2013 Dec 23.
Background. The most common chemotherapies in metastatic soft tissue sarcoma (mSTS) require intravenous (IV) administration. This often requires patients to make multiple outpatient visits per chemotherapy cycle, possibly impeding patients' daily activities and increasing caregiver burden and medical costs. This study investigated costs associated with IV cancer therapy administration in mSTS from the payer perspective of the health care system. Patients and Methods. From the Experian Healthcare database, 1,228 mSTS patients were selected. Data were analyzed on outpatient visits during 2005-2012 involving IV cancer therapy administration. Costs were estimated on a per patient per visit (PPPV) and per patient per month (PPPM) basis. Results. The mean (median) cost of IV therapy was $2,427 ($1,532) PPPV and $5,468 ($4,310) PPPM, of which approximately 60% was IV drug costs. IV administration costs averaged $399 PPPV and $900 PPPM, representing 16.5% of total visit costs. Anthracycline and alkylating-agents-based therapies had the highest PPPV and PPPM IV administration costs, respectively (mean $479 and $1,336, resp.). Patients with managed care insurance had the highest IV administration costs (mean $504 PPPV; $1,120 PPPM). Conclusions. IV administration costs constitute a considerable proportion of the total costs of receiving an IV cancer therapy to treat mSTS.
背景。转移性软组织肉瘤（mSTS）最常见的化疗需要静脉注射（IV）给药。这通常要求患者在每个化疗周期进行多次门诊就诊，可能会妨碍患者的日常活动，并增加护理人员负担和医疗成本。本研究从医疗保健系统支付方的角度调查了mSTS中静脉癌症治疗给药的相关成本。患者与方法。从益百利医疗数据库中选取了1228例mSTS患者。对2005 - 2012年期间涉及静脉癌症治疗给药的门诊就诊数据进行了分析。成本按每次就诊每位患者（PPPV）和每月每位患者（PPPM）进行估算。结果。静脉治疗的平均（中位数）成本为每次就诊每位患者2427美元（1532美元）PPPV和每月每位患者5468美元（4310美元）PPPM，其中约60%为静脉药物成本。静脉给药成本平均为每次就诊每位患者399美元和每月每位患者900美元，占总就诊成本的16.5%。基于蒽环类药物和烷化剂的疗法分别具有最高的PPPV和PPPM静脉给药成本（分别平均为479美元和1336美元）。拥有管理式医疗保险的患者静脉给药成本最高（平均每次就诊每位患者504美元；每月每位患者1120美元）。结论。静脉给药成本在接受静脉癌症治疗以治疗mSTS的总成本中占相当大的比例。
